Arvinas logo
Close this search box.

PROTAC® BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors

James D. Winkler

March 4, 2016
14th International Congress on Targeted Anticancer Therapies (TAT)


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content